Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 2/20 | 0.39 |
| ▸ | POLG | P54098 | 2/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099313 | 1.00 | PDE3A (0.40) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL17109612 | 1.00 | PDE3A (0.40) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL20221826 | 0.92 | PDE3A (0.43) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL20221801 | 0.92 | PDE3A (0.43) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL17099314 | 0.91 | PDE3A (0.40) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL17109557 | 0.88 | PDE3A (0.39) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL16480770 | 0.83 | POLA1 (0.35) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL15588664 | 0.83 | POLA1 (0.35) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL15588667 | 0.83 | POLA1 (0.35) | PDE3APDE4DSLC29A1POLA1POLG | |
| SCHEMBL16480787 | 0.83 | POLA1 (0.35) | PDE3APDE4DSLC29A1POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | ZHONG MINGHONG (US) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | TYMP, ENPP3, PNP | PDE3A 2138/4885PDE4D 1343/4885SLC29A1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.